{"id":"gp-plus-placebo-induction-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297963","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This appears to be a clinical trial protocol rather than a defined drug entity. 'GP' likely refers to a specific therapeutic agent (possibly gemcitabine-based or another regimen), combined with placebo control in an induction phase design. The exact mechanism depends on the identity of the 'GP' component, which is not specified in the available information.","oneSentence":"GP plus placebo induction therapy is an investigational treatment regimen that combines a primary active agent with placebo in an induction phase to evaluate therapeutic efficacy and safety.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:12.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07337096","phase":"NA","title":"Electro-Acupuncture in Lung cancER : EALER Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors","enrollment":424},{"nctId":"NCT07027566","phase":"PHASE1","title":"Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity","status":"NOT_YET_RECRUITING","sponsor":"Universidade Federal do Para","startDate":"2025-07-25","conditions":"Dentin Sensitivity","enrollment":75},{"nctId":"NCT06060028","phase":"NA","title":"The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2023-07-06","conditions":"Chronic Pain","enrollment":60},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT05211232","phase":"PHASE3","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-10","conditions":"Nasopharyngeal Carcinoma","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP plus placebo induction therapy","genericName":"GP plus placebo induction therapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}